Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of ferric carboxymaltose on exercise in chronic heart failure with iron deficiency
2008-001503-26Phase 3Terminated
- Sponsor
- Vifor Pharma
- Start
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic heart failure (CHF) and iron deficiency anemia (IDA) comparing Ferric carboxymaltose with Placebo (2 arms). Primary endpoint: Co-primary outcomes. Started Aug 2008; status: terminated.
02
Drugs
ferric carboxymaltose
03
Conditions
chronic heart failure (CHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on 2008-001503-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001503-26.